Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

BACKGROUND AND OBJECTIVES: Benralizumab is a humanized, afucosylated monoclonal antibody against the IL-5Rα. Initial monthly followed by every-other-month injections result in rapid and nearly complete eosinophil depletion. We evaluated whether three doses of benralizumab modifies antibody response...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeitlin, Pamela L, Leong, Mila, Cole, Jeremy, Mallory, Raburn M, Shih, Vivian H, Olsson, Richard F, Goldman, Mitchell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248228/
https://www.ncbi.nlm.nih.gov/pubmed/30510434
http://dx.doi.org/10.2147/JAA.S172338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248228/
https://www.ncbi.nlm.nih.gov/pubmed/30510434
http://dx.doi.org/10.2147/JAA.S172338

Ejemplares similares